

# Arginine Catabolic Mobile Element in Methicillin-Resistant *Staphylococcus aureus* (MRSA) Clonal Group ST239-MRSA-III Isolates in Singapore: Implications for PCR-Based Screening Tests

Pei Yun Hon,<sup>a</sup> Kian Sing Chan,<sup>b</sup> Matthew T. Holden,<sup>c</sup> Simon R. Harris,<sup>c</sup> Thean Yen Tan,<sup>d</sup> Yan-Bing Zu,<sup>e</sup> Prabha Krishnan,<sup>f</sup> Lynette L. Oon,<sup>b</sup> Tse Hsien Koh,<sup>b</sup> Li Yang Hsu<sup>a</sup>

Department of Medicine, National University Health System, Singapore, Singapore<sup>a</sup>; Department of Pathology, Singapore General Hospital, Singapore, Singapore<sup>b</sup>; Pathogen Genomics, Wellcome Trust Sanger Institute, Hinxton, Cambridge, United Kingdom<sup>c</sup>; Department of Laboratory Medicine, Changi General Hospital, Singapore, Singapore<sup>d</sup>; Institute of Bioengineering and Nanotechnology, Singapore, Singapore<sup>e</sup>; Department of Laboratory Medicine, Tan Tock Seng Hospital, Singapore, Singapore<sup>f</sup>

Espedido and coworkers found that up to 38.7% of methicillin-resistant *Staphylococcus aureus* (MRSA) clonal group ST239-MRSA-III strains in a Sydney hospital carried an arginine catabolic mobile element (ACME) type II variant that inserted between *orfX* and the staphylococcal cassette chromosome *mec* element (SCC*mec*) (1), whereas Ghaznavi-Rad and coworkers detected ACME in 1.1% of ST239-MRSA-III strains isolated from a Kuala Lumpur hospital, but did not specify its insertion point (2). The practical implications of such strains cannot be underestimated, especially in institutions where MRSA screening is predominantly performed using commercial molecular tests, because the majority of these currently detect the presence of sequences in the junction between *orfX* and SCC*mec*, and will potentially yield

false-negative results if the sequences on the two sides of the junction are separated by a 13-kb ACME insertion.

Given Singapore's geographical proximity to and relations with Australia and Malaysia, we postulated that such ACME-positive strains are likely to be present locally. We had recently assembled a randomly selected sample of 110 clinical ST239-MRSA-III

Published ahead of print 14 January 2013

Address correspondence to Li Yang Hsu, liyang\_hsu@yahoo.com.

Copyright © 2013, American Society for Microbiology. All Rights Reserved.

doi:10.1128/AAC.02518-12




FIG 1 Distribution of ACME-positive ST239 MRSA strains in Singaporean hospitals over time. The sole ACME-positive MRSA strain where the insertion point was outside the *orfX*-SCC*mec* junction was isolated in 2008.

strains isolated between 2000 and 2010 from 3 local hospitals for whole-genome sequencing, which was performed following previously described protocols (3, 4). *De novo* assembly of the genomes using Velvet v0.7.03 (5) revealed 14 (12.7%) ST239 strains with ACME, and contigs bridging *orfX* and ACME as well as ACME and *SCCmec* III were found in 13 of the strains, whereas one strain appeared to have ACME inserted before *sasH* (data not shown). This was confirmed by *orfX*-ACME-specific PCR (1), which was positive for the initial 13 strains and negative for the last. None of the ST22-MRSA strains carried ACME.

The distribution of ACME-positive ST239 strains—which were present in all 3 hospitals—is shown in Fig. 1. Despite the small number of ST239 strains collected each year, it is striking that ACME tests were positive in at least 20% of ST239-MRSA strains isolated since 2006, and that virtually all (92.9%) strains had ACME inserted into the *orfX*-*SCCmec* junction.

As proof of concept, we ran saline suspensions of six of these clinical strains (viable counts ranging from  $1.8$  to  $8.2 \times 10^3$  CFU/ml) along with an ACME-negative MRSA strain (ATCC BAA-1026; viable count,  $1.6 \times 10^2$  CFU/ml) control on the Xpert MRSA assay (Cepheid, Sunnyvale, CA), following the manufacturer's instructions. Only the ATCC MRSA strain and the strain with ACME inserted outside the *orfX*-*SCCmec* junction yielded strongly positive results, while all the other strains were negative on the Xpert MRSA system. Parallel aliquots of these suspensions were plated and subsequently demonstrated good growth of MRSA colonies that again tested positive on *mecA* PCR (6). Although we did not test other commercial *orfX*-*SCCmec* molecular MRSA assays, it is extremely unlikely that these would be able to detect such ACME-positive MRSA strains.

Our results suggest that ST239-MRSA-III strains with ACME inserted between *orfX* and *SCCmec* are an emerging threat in the region. The inability of current commercial *orfX*-*SCCmec* molecular tests to detect such strains will complicate MRSA control

efforts wherever such strains are prevalent, and institutions where ST239 is the prevalent MRSA clone are advised to test for the prevalence of such strains prior to investing in current commercial molecular testing platforms for MRSA.

## ACKNOWLEDGMENTS

The work was partially supported by the Wellcome Trust (grant 098051) and a National Medical Research Council (Singapore) Research Training Fellowship grant.

## REFERENCES

1. Espedido BA, Steen JA, Barbagiannakos T, Mercer J, Paterson DL, Grimmond SM, Cooper MA, Gosbell IB, van Hal SJ, Jensen SO. 2012. Carriage of an ACME II variant may have contributed to methicillin-resistant *Staphylococcus aureus* sequence type 239-like strain replacement in Liverpool Hospital, Sydney, Australia. *Antimicrob. Agents Chemother.* 56:3380–3383.
2. Ghaznavi-Rad E, Nor Shamsudin M, Sekawi Z, Khoon LY, Aziz MN, Hamat RA, Othman N, Chong PP, van Belkum A, Ghasemzadeh-Moghaddam H, Neela V. 2010. Predominance and emergence of clones of hospital-acquired methicillin-resistant *Staphylococcus aureus* in Malaysia. *J. Clin. Microbiol.* 48:867–872.
3. Harris SR, Feil EJ, Holden MT, Quail MA, Nickerson EK, Chantratita N, Gardete S, Tavares A, Day N, Lindsay JA, Edgeworth JD, de Lencastre H, Parkhill J, Peacock SJ, Bentley SD. 2010. Evolution of MRSA during hospital transmission and intercontinental spread. *Science* 327:469–474.
4. Köser CU, Holden MT, Ellington MJ, Cartwright EJ, Brown NM, Ogilvy-Stuart AL, Hsu LY, Chewapreecha C, Croucher NJ, Harris SR, Sanders M, Enright MC, Dougan G, Bentley SD, Parkhill J, Fraser LJ, Betley JR, Schulz-Trieglaff OB, Smith GP, Peacock SJ. 2012. Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. *N. Engl. J. Med.* 366:2267–2275.
5. Zerbino DR. 2010. Using the Velvet *de novo* assembler for short-read sequencing technologies. *Curr. Protoc. Bioinformatics* 31:11.5.1–11.5.12. doi:10.1002/0471250953.b11105s31.
6. Oliveira DC, de Lencastre H. 2002. Multiplex PCR strategy for rapid identification of structural types and variants of the *mec* element in methicillin-resistant *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 46:2155–2161.